OncoMatch/Clinical Trials/NCT06266832
The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma
Is NCT06266832 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Adebrelimab and Oxaliplatin for rectal adenocarcinoma.
Treatment: Adebrelimab · Oxaliplatin · Capecitabine — To evaluate the efficacy, safety and organ retention rate of short-course radiation combined with Adebrelimab and CAPEOX neoadjuvant therapy in patients with MSS/pMMR ultra low rectal adenocarcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Required: MSH2 proficient MMR
MMR protein detection or MSI gene detection of rectal cancer specimens confirmed pMMR or MSS before treatment
Required: MSH6 proficient MMR
MMR protein detection or MSI gene detection of rectal cancer specimens confirmed pMMR or MSS before treatment
Required: MLH1 proficient MMR
MMR protein detection or MSI gene detection of rectal cancer specimens confirmed pMMR or MSS before treatment
Required: PMS2 proficient MMR
MMR protein detection or MSI gene detection of rectal cancer specimens confirmed pMMR or MSS before treatment
Required: MSH2 microsatellite stable
MMR protein detection or MSI gene detection of rectal cancer specimens confirmed pMMR or MSS before treatment
Required: MSH6 microsatellite stable
MMR protein detection or MSI gene detection of rectal cancer specimens confirmed pMMR or MSS before treatment
Required: MLH1 microsatellite stable
MMR protein detection or MSI gene detection of rectal cancer specimens confirmed pMMR or MSS before treatment
Required: PMS2 microsatellite stable
MMR protein detection or MSI gene detection of rectal cancer specimens confirmed pMMR or MSS before treatment
Disease stage
Required: Stage I, II, III
Excluded: Stage IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
White blood cell count >3.5×10^9/L, absolute value of neutrophils >1.8×10^9/L, platelet count ≥75×10^9/L, hemoglobin ≥100g/L
Kidney function
24h creatinine clearance >50mL/min or serum creatinine <1.5 times the upper limit of normal
Liver function
Total bilirubin ≤ 1.25 times the upper limit of normal; ALT and AST < 5 times the upper limit of normal
Laboratory inspections must meet the following standards: White blood cell count >3.5×10^9/L, absolute value of neutrophils >1.8×10^9/L, platelet count ≥75×10^9/L, hemoglobin ≥100g/L; INR≤1.5, and APTT≤1.5 times the upper limit of normal or partial prothrombin time (PT) ≤1.5 times the upper limit of normal; Total bilirubin ≤ 1.25 times the upper limit of normal; ALT and AST < 5 times the upper limit of normal; 24h creatinine clearance >50mL/min or serum creatinine <1.5 times the upper limit of normal.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify